<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01505946</url>
  </required_header>
  <id_info>
    <org_study_id>PredicTGA</org_study_id>
    <secondary_id>373</secondary_id>
    <nct_id>NCT01505946</nct_id>
  </id_info>
  <brief_title>Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors</brief_title>
  <acronym>PredicTGA</acronym>
  <official_title>Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic Effectiveness of Factor VIII (FVIII) Concentrates in Patients Affected by Inherited Haemophilia A With FVIII Inhibitors High and Low Anamnestic Response.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grifols Italia S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrombinoscope</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Grifols Italia S.p.A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational, prospective, longitudinal, multicenter, cohort study designed with
      the scope to verify whether or not TGA may predict effectiveness of different FVIII
      concentrates class (devoid or rich of VWF) in patient affected by severe or moderately severe
      inherited haemophilia A and inhibitors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:

      Hemophilia A is a serious and common hereditary bleeding disorder caused by deficiency of
      coagulation factor VIII (FVIII). Patients with this disease are treated with recombinant
      factor VIII or factor VIII concentrates derived from plasma.

      Administration of exogenous FVIII in 15-35% of cases, cause the formation of antibodies to
      FVIII (inhibitors) that neutralize the activity of factor VIII, making the treatment
      ineffective.The development of inhibitors of factor VIII (FVIII) is the most serious and
      challenging complication of the treatment of hemophilia A and represents the highest economic
      burden for a chronic disease. Therefore, research is making great efforts to optimize the
      best therapeutic approach for the disease.

      It has been observed that FVIII inhibitors display a wide range of immunoreactivity when
      tested against different classes of FVIII concentrates (with/without von Willebrand factor
      -VWF). It has been demonstrated that the different inhibitors reactivity may correlate with
      different ability of inhibitors to impair thrombin generation, as tested by Thrombin
      Generation Assay (TGA). In these patients TGA assay might be a tool to predict which FVIII
      concentrate has the greater haemostatic effectiveness.

      It is also uncertain if the different classes of FVIII used in ITI protocols may have a
      different effectiveness in reducing the occurrence of BT bleedings and if this may correlate
      to lower reactivity, epitope specificity, VWF content and may be predicted by TGA. It would
      be very helpful to be able to give an evidence based diagnostic and prognostic instrument,
      the TGA, to aid physician to optimize the therapy for all inhibitors patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombin generation result</measure>
    <time_frame>12 months</time_frame>
    <description>Thrombin generation results of the TGA applied on plasma patients whith inhibitor matched with different class of FVIII concentrate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epitope mapping results</measure>
    <time_frame>12 months</time_frame>
    <description>epitope mapping test on the plasma patient during the therapy for a follow-up period of 12 month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of all breakthrough (BT) bleedings</measure>
    <time_frame>12 months</time_frame>
    <description>events/month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total FVIII dose required to treat the patients</measure>
    <time_frame>12 months</time_frame>
    <description>(IU/year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the inhibitor titre course</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of bypassing agents</measure>
    <time_frame>12 months</time_frame>
    <description>incidence of BT bleedings who require bypassing agents (events/months) average dose of bypassing agents (or days of treatment) needed to treat BT bleedings total dose of bypassing agent (and days of treatment) required overall (IU/year) and (days of treatment/year)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ITI outcome only for patient under this kind of treatment</measure>
    <time_frame>3 years</time_frame>
    <description>% of Success (total, partial success or failure will be defined as in ITI study protocol) Time to tolerance (months), defined as the time to ITI success (total/partial)</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Severe Hemophilia A With Inhibitor</condition>
  <arm_group>
    <arm_group_label>LOW RESPONDERS</arm_group_label>
    <description>Documented low anamnestic response after FVIII exposure (FVIII inhibitors titre &gt;0.6 and &lt; 5 BU/ml tested by Bethesda assay, Nijmegen modification). Patients who have never been submitted to ITI and also those patients who have completed ITI with partial success (defined as inhibitors titre &gt;0.6 and &lt; 5 BU/ml and no increase in the INH titer &gt; 5 BU over treatment with FVIII)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIGH RESPONDERS</arm_group_label>
    <description>Patients who documented high response after FVIII exposure (FVIII inhibitors titre &gt; 5 BU/ml tested by Bethesda assay, Nijmegen modification) and who are potential candidates to a first or rescue ITI</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TGA (Thrombin generation Assay)</intervention_name>
    <description>TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the &quot;most effective&quot;. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period</description>
    <arm_group_label>LOW RESPONDERS</arm_group_label>
    <arm_group_label>HIGH RESPONDERS</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with moderate or severe hemophilia A with inhibitors divided into two groups:

          1. Patients with inhibitors to FVIII and low anamnestic response: Low responders cohort

          2. Patients with inhibitors to FVIII and high anamnestic response: High responders cohort
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of inherited, severe (FVIII:C &lt; 1%) or moderately severe haemophilia A
             (FVIII ≤ 2%)

          -  Any age

          -  Ability to comply with study methods and willingness to participate to the study

          -  Written informed consent.

        FOR THE LOW RESPONDERS COHORT

        - Documented low anamnestic response after FVIII exposure (FVIII inhibitors titre &gt;0.6 and
        &lt; 5 BU/ml tested by Bethesda assay, Nijmegen modification). It will be included in this
        study those patients who have never been submitted to ITI and also those patients who have
        completed ITI with partial success (defined as inhibitors titre &gt;0.6 and &lt; 5 BU/ml and no
        increase in the INH titer &gt; 5 BU over treatment with FVIII)

        INCLUSION CRITERIA FOR THE HIGH RESPONDERS COHORT

          -  Documented high response after FVIII exposure (FVIII inhibitors titre &gt; 5 BU/ml tested
             by Bethesda assay, Nijmegen modification). It will be included in this study those
             patients who are potential candidates to a first or rescue ITI.

          -  Any historical peak ≥ 5 BU

        Exclusion Criteria:

          -  Diagnosis of acquired haemophilia

          -  Diagnosis of inherited mild haemophilia A (FVIII &gt; 2%)

          -  Life expectancy lower than 1 year

          -  Psychiatric illness and any other conditions may impair ability to comply with study
             methods
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Santagostino, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Angelo Bianchi Bonomi&quot; Haemophilia Thrombosis Centre I.R.C.S.S. Maggiore Hospital and University of Milan Via Pace 9, 20122 Milan - Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elena Santagostino, Scientific Coordinator</last_name>
    <phone>+39 02 55035273</phone>
    <email>hemophilia_ctr@policlinico.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa Mancuso</last_name>
    <phone>+39 02 55035273</phone>
    <email>hemophilia_ctr@policlinico.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ospedale Civile dell' Annunziata</name>
      <address>
        <city>Cosenza</city>
        <state>Calabria</state>
        <zip>87100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filomena Daniele, MD</last_name>
      <email>fildaniele@libero.it</email>
    </contact>
    <investigator>
      <last_name>Filomena Daniele, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az. Universitaria Policlinico &quot;Federico II&quot; Dip. Assist. di Clinica Medica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UO Angiologia e Malattie della Coagulazione &quot;Marino Golinelli&quot; Az Osp. Policlinico S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>Emilia Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lelia Valdrè, MD</last_name>
      <email>lvaldre@aosp.bo.it</email>
    </contact>
    <investigator>
      <last_name>Gualtiero Palareti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lelia Valdrè, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giuseppina Rodorigo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera &quot;Santa Maria della Misericordia&quot;</name>
      <address>
        <city>Udine</city>
        <state>Friuli Venezia Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Barillari, MD</last_name>
      <email>barillari.giovanni@aoud.sanita.fvg.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Barillari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samantha Pasca, BS PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Dipartimento di Biotecnologie Cellulari Università La Sapienza - Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù di Roma</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matteo Luciani, MD</last_name>
      <email>matteo.luciani@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Matteo Luciani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Cattolica - Policlinico A. Gemelli</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedialiera Ospedale Infantile Regina Margherita - S.Anna</name>
      <address>
        <city>Turin</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Messina, MD</last_name>
      <email>maria.messina@oirmsantanna.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Maria Messina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Berardino Pollio, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Le Molinette &quot;S. G. Battista&quot;</name>
      <address>
        <city>Turin</city>
        <state>Piemonte</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Borchiellini, MD</last_name>
      <email>aborchiellini@molinette.piemonte.it</email>
    </contact>
    <investigator>
      <last_name>Alessandra Borchiellini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Consorziale Policlinico di Bari</name>
      <address>
        <city>BAri</city>
        <state>Puglia</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Agenzia per l'Emofilia Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Florence</city>
        <state>Tuscany</state>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Massimo Morfini, MD</last_name>
      <email>massimo.morfini@unfi.it</email>
    </contact>
    <investigator>
      <last_name>Massimo Morfini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silvia Linari, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Az. Ospedaliera di Padova, Clinica Medica IIa</name>
      <address>
        <city>Padua</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ezio Zanon, MD</last_name>
      <email>ezio.zanon@unipd.it</email>
    </contact>
    <investigator>
      <last_name>Ezio Zanon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Univesitaria Integrata di Verona - Borgo Roma</name>
      <address>
        <city>Verona</city>
        <state>Veneto</state>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Terapie Cellulari ed Ematologia Ospedale San Bortolo</name>
      <address>
        <city>Vicenza</city>
        <state>Veneto</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giancarlo Castaman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giancarlo Castaman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di Riferimento Emostasi e Trombosi in età pediatrica Ospedale dei bambini G. Di Cristina</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Gagliano, Physician</last_name>
      <email>ematopediatriaob@teletu.it</email>
    </contact>
    <investigator>
      <last_name>Fabio Gagliano, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003 Jul;9(4):418-35. Review.</citation>
    <PMID>12828678</PMID>
  </reference>
  <reference>
    <citation>Salvagno GL, Astermark J, Ekman M, Franchini M, Guidi GC, Lippi G, Poli G, Berntorp E. Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation. Haemophilia. 2007 Jan;13(1):51-6.</citation>
    <PMID>17212725</PMID>
  </reference>
  <reference>
    <citation>Iorio A, Halimeh S, Holzhauer S, Goldenberg N, Marchesini E, Marcucci M, Young G, Bidlingmaier C, Brandao LR, Ettingshausen CE, Gringeri A, Kenet G, Knöfler R, Kreuz W, Kurnik K, Manner D, Santagostino E, Mannucci PM, Nowak-Göttl U. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost. 2010 Jun;8(6):1256-65. doi: 10.1111/j.1538-7836.2010.03823.x. Epub 2010 Mar 17. Review.</citation>
    <PMID>20345722</PMID>
  </reference>
  <reference>
    <citation>Astermark J, Santagostino E, Keith Hoots W. Clinical issues in inhibitors. Haemophilia. 2010 Jul;16 Suppl 5:54-60. doi: 10.1111/j.1365-2516.2010.02294.x. Review.</citation>
    <PMID>20590857</PMID>
  </reference>
  <reference>
    <citation>Gringeri A, Mantovani LG, Scalone L, Mannucci PM; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood. 2003 Oct 1;102(7):2358-63. Epub 2003 Jun 19.</citation>
    <PMID>12816859</PMID>
  </reference>
  <reference>
    <citation>Kopecky EM, Greinstetter S, Pabinger I, Buchacher A, Römisch J, Jungbauer A. Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays. J Immunol Methods. 2006 Jan 20;308(1-2):90-100. Epub 2005 Dec 5.</citation>
    <PMID>16376372</PMID>
  </reference>
  <reference>
    <citation>Chambost H. Assessing risk factors: prevention of inhibitors in haemophilia. Haemophilia. 2010 Mar;16 Suppl 2:10-5. doi: 10.1111/j.1365-2516.2009.02197.x. Review.</citation>
    <PMID>20132333</PMID>
  </reference>
  <reference>
    <citation>Boekhorst J, Lari GR, D'Oiron R, Costa JM, Nováková IR, Ala FA, Lavergne JM, VAN Heerde WL. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations. Haemophilia. 2008 Jul;14(4):729-35. doi: 10.1111/j.1365-2516.2008.01694.x. Epub 2008 May 12.</citation>
    <PMID>18503540</PMID>
  </reference>
  <reference>
    <citation>Coppola A, Margaglione M, Santagostino E, Rocino A, Grandone E, Mannucci PM, Di Minno G; AICE PROFIT Study Group. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost. 2009 Nov;7(11):1809-15. doi: 10.1111/j.1538-7836.2009.03615.x. Epub 2009 Sep 9.</citation>
    <PMID>19740093</PMID>
  </reference>
  <reference>
    <citation>Kallas A, Talpsep T. von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients. Haemophilia. 2001 Jul;7(4):375-80.</citation>
    <PMID>11442642</PMID>
  </reference>
  <reference>
    <citation>Astermark J, Voorberg J, Lenk H, DiMichele D, Shapiro A, Tjönnfjord G, Berntorp E. Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro. Haemophilia. 2003 Sep;9(5):567-72.</citation>
    <PMID>14511295</PMID>
  </reference>
  <reference>
    <citation>Berntorp E. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance? Haematologica. 2003 Jun;88(6):EREP03. Review.</citation>
    <PMID>12826529</PMID>
  </reference>
  <reference>
    <citation>Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia. 2007 Dec;13 Suppl 5:73-7. doi: 10.1111/j.1365-2516.2007.01579.x.</citation>
    <PMID>18078402</PMID>
  </reference>
  <reference>
    <citation>Goudemand J, Rothschild C, Demiguel V, Vinciguerrat C, Lambert T, Chambost H, Borel-Derlon A, Claeyssens S, Laurian Y, Calvez T; FVIII-LFB and Recombinant FVIII study groups. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006 Jan 1;107(1):46-51. Epub 2005 Sep 15.</citation>
    <PMID>16166584</PMID>
  </reference>
  <reference>
    <citation>Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM; Emoclot15 Study Members. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia. 2006 Mar;12(2):128-32.</citation>
    <PMID>16476086</PMID>
  </reference>
  <reference>
    <citation>Kurth MA, Dimichele D, Sexauer C, Sanders JM, Torres M, Zappa SC, Ragni M, Leonard N. Immune tolerance therapy utilizing factor VIII/von Willebrand factor concentrate in haemophilia A patients with high titre factor VIII inhibitors. Haemophilia. 2008 Jan;14(1):50-5. Epub 2007 Oct 18. Erratum in: Haemophilia. 2008 Jul;14(4):878. Haemophilia. 2008 Mar;14(2):414.</citation>
    <PMID>17941829</PMID>
  </reference>
  <reference>
    <citation>Orsini F, Rotschild C, Beurrier P, Faradji A, Goudemand J, Polack B. Immune tolerance induction with highly purified plasma-derived factor VIII containing von Willebrand factor in hemophilia A patients with high-responding inhibitors. Haematologica. 2005 Sep;90(9):1288-90.</citation>
    <PMID>16154861</PMID>
  </reference>
  <reference>
    <citation>Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM; RITS-FITNHES Study Group. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response. Haemophilia. 2007 Jul;13(4):373-9.</citation>
    <PMID>17610550</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2012</study_first_submitted>
  <study_first_submitted_qc>January 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2012</study_first_posted>
  <last_update_submitted>June 14, 2013</last_update_submitted>
  <last_update_submitted_qc>June 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Thrombin</keyword>
  <keyword>Hemophilia</keyword>
  <keyword>Inhibitors</keyword>
  <keyword>Immunotolerance</keyword>
  <keyword>Haemostatic</keyword>
  <keyword>FVIII</keyword>
  <keyword>Epitopes</keyword>
  <keyword>Moderately severe Hemophilia A with inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
    <mesh_term>Thrombin</mesh_term>
    <mesh_term>Factor VIII</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

